Join
Live feed
·
PRReleasevia Quantisnow
AN2 Therapeutics Inc. logo

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

ByQuantisnow·Wall Street's wire, on your screen.
ANTX· AN2 Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANTX (AN2 Therapeutics Inc.) and more on Quantisnow.